AbbVie After Purchase Apogee? Is It a Buy Now for Investors
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
Identify the conditions under which bonds may be preferable to SP 500 for retirement, emphasizing income reliability and capital preservation.
24,428 articlesAbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
Qualcomm is shifting focus from phones to AI compute, targeting massive new markets. This article breaks down the pla...
A former Meta public policy director alleges the company spied on her for more than a year to suppress discussion of ...
A high-profile art deal turned sour when a previously convicted fraudster accused used lies to push a price down and ...
Savara investors should stay focused on how insider moves and regulatory timelines interact with a growing biotech st...
David Rahal, founder and CEO of David Protein, argues GLP-1 drugs have upended the diet-trend cycle, reshaping how br...
Saylor’s Strategy rolls out a Digital Credit Capital Framework to bolster BTC exposure and liquidity, aiming to calm ...
Illinois becomes the first state to tax crypto by transaction, signaling how states may monetize digital assets even ...
As U.S. AI export controls tighten, investors face a push-pull: tighter access could spur China’s open-source AI ecos...
Warren Buffett has paused his annual gift to the Gates Foundation, signaling a shift in a years-long philanthropic pa...
A high-stakes NBA scenario puts investor attention on payroll, sponsorships, and market bets. The potential LeBron mo...
A major market moment is shaping up as Dan Ives weighs in on SpaceX’s potential public debut. This article breaks dow...